The MRIdian system is designed to integrate full-time MR imaging, cobalt radiation delivery and software automation for cancer treatment throughout the body, the Cleveland, Ohio-based company said.
In a release posted yesterday, ViewRay said that it signed an agreement with Australia’s Device Technologies to distribute the device in the region.
“We’re delighted to be including ViewRay’s MRIdian in the portfolio of high-end innovative products for distribution in Australia and New Zealand. We always put our patients first, and MRIdian’s simultaneous MRI imaging and radiation therapy provides highly accurate delivery of radiation to the patient, which helps enable an optimal clinical outcome in a shorter timeframe,” Device Technologies Australia CEO Mick Trevaskis said in a prepared statement.
ViewRay said today that it also signed a deal with Canadian distributor Minogue Medical to distribute the MRIdian MRI-guided radiation therapy system throughout the country.
“We are excited to continue to bring innovative technologies to Canadian hospitals and patients. MRIdian’s MRI-guided radiation therapy will help provide Canadians with accurate, efficient, optimized care to help ensure excellent outcomes for patients,” Minogue Medical CEO Danny Minogue said in a press release.
“Device Technologies is the ideal partner to bring the benefits of the MRIdian System to one of the biggest and best healthcare markets in the world. Device Technologies has successfully sold, implemented and supported many other high-tech medical devices, so we’re confident given the growing excitement around MRI-guided radiation therapy, that they will deliver equally impressive results with MRIdian,” chief commercial officer Jim Alecxih said in a prepared release. “The medical device market in Canada is strong and sophisticated, with a high demand for innovative medical technologies. We’re pleased to partner with Minogue Medical to bring MRIdian to the Canadian healthcare system and improve the accuracy and precision of radiation therapy throughout the country.”
In February, ViewRay said that it won FDA 510(k) clearance to offer soft tissue visualization capabilities with its MRIdian system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.